Journal

One in Nine American Adults Now Takes a GLP-1 — and Obesity Rates Are Falling

Current use has nearly quadrupled in two years, and the national obesity rate has dropped for the first time in decades.

The numbers

Gallup's National Health and Well-Being Index, surveying 5,065 adults between 28 May and 5 June 2026, found current GLP-1 use for weight loss at 11% of US adults. In 2024 the same measure was 3%. Fifteen per cent reported having used these drugs at some point.

Across the same window, the US adult obesity rate declined from its 2022 peak of 39.9% to 36.4%, and diabetes diagnoses stabilised.

What this does and does not establish

A population-level correlation between rising treatment and falling prevalence is suggestive and not conclusive. Survey-reported medication use is self-reported. Obesity prevalence moves for many reasons. And the two datasets were not designed to be linked.

What can be said more confidently is that adoption at this scale is genuinely unusual in pharmacotherapy, and that it has happened faster than the evidence base for long-term use has accumulated. The longest published follow-up in this field is the three-year SURMOUNT-1 prediabetes analysis. Millions of people are now taking these drugs on an open-ended basis with roughly three years of controlled data behind that decision.

Why adoption accelerated when it did

Three things changed within eighteen months.

Oral options arrived. The Wegovy pill launched January 2026; Foundayo followed in April. Needle avoidance was a real barrier for a substantial group.

Brand prices fell sharply. Zepbound is now $299 to $449 direct from LillyDirect; Wegovy $349 from NovoCare, with both oral products starting at $149. Eighteen months ago list prices above $1,000 were the reference point.

Medicare opened a door. The GLP-1 Bridge began 1 July 2026, providing eligible Part D enrollees certain GLP-1s at a flat $50 copay through the end of 2027.

What the adoption curve hides

Discontinuation. Fifteen per cent have ever used these drugs and 11% currently do, which implies a meaningful group who started and stopped. In SURMOUNT-1, 4.3% to 7.1% discontinued because of an adverse event depending on dose.

And SURMOUNT-4 found that people withdrawn from tirzepatide after a lead-in regained 14% of body weight over the following year, while those continuing lost a further 5.5%. If a substantial share of the ever-used group has stopped, some proportion of the population-level benefit is temporary.

What it means for someone deciding now

Scale is not evidence of appropriateness for you. Forty million users tells you the market moved; it does not tell you whether the drug suits your history, your tolerability or your circumstances.

Two things are worth doing before the price comparison. Establish whether you have coverage — commercial plans that cover these drugs can bring the cost near $25, and the Medicare Bridge is $50, both below every self-pay route including every compounded programme. And establish the plan for continuation, because the evidence suggests the relevant cost is indefinite rather than annual.

What a survey measure can and cannot show

Gallup's figure is self-reported current use among 5,065 adults surveyed between 28 May and 5 June 2026. Survey measures capture what people say they do, which is generally reliable for prescription medication but not identical to dispensing data.

The obesity prevalence figures come from separate national measurement. Two independent datasets moving in opposite directions over the same period is suggestive; it is not a designed study of one causing the other.

The discontinuation gap

Fifteen per cent report ever-use and 11% report current use. That four-point gap represents people who started and stopped — millions of them.

Some stopped because of side effects; SURMOUNT-1 recorded 4.3% to 7.1% discontinuation for adverse events depending on dose. Some stopped because of cost. Some because supply changed. The survey does not separate them, and no published dataset does it well.

It matters because SURMOUNT-4 found that withdrawal was followed by 14% weight regain over the following year. Population-level benefit accrues to people who continue, and a meaningful share have not.

What changed in eighteen months to produce this

Oral options arrived — the Wegovy pill in January 2026, Foundayo in April. Brand prices fell sharply, with Zepbound now $299 to $449 direct and both approved orals starting at $149. And Medicare opened access on 1 July 2026 through the GLP-1 Bridge at a flat $50 copay for eligible enrollees.

Each removed a different barrier: needles, price, and coverage.

What it should not change about your decision

Scale is not evidence of appropriateness. Forty million users tells you the market moved. It does not tell you whether this suits your history, your tolerability or your circumstances — and it does not shorten the list of questions worth asking a clinician first.

Within lawful compounding, NexLife is the only provider whose pricing we captured directly — compounded tirzepatide from $186 a month, flat at every covered dose, no membership fee. See its plans.

Questions readers actually ask